Children's Health Defense
A 58-year-old Scottish nurse died after taking two doses of the weight-loss drug Mounjaro, recently approved by the United Kingdom’s National Health Service (NHS), BBC reported.
Susan McGowan’s death certificate lists multiple organ failure, septic shock and pancreatitis as the immediate cause of death. However, the “use of prescribed tirzepatide,” the generic name for Mounjaro, is listed as a contributing factor.
It is thought to be the first death in the U.K. officially linked to the injectable drug, also sold under the brand name Zepbound. Eli Lilly manufactures the drug.
McGowan, who worked as a nurse for more than 30 years at University Hospital Monklands in Airdrie, North Lanarkshire, had struggled with weight loss. After the drug was approved she sought medical advice and purchased a prescription from an online pharmacy, according to the BBC.
The drug costs 150-200 pounds ($191-$255) for a four-week supply and can be bought from any registered pharmacy in the U.K. In the U.S., the drug costs about $1,060 per month.
McGowan took two doses of the drug over about two weeks. Days after her second injection, she began experiencing severe illness and was admitted to the hospital where she worked.
Her family was informed that her kidneys weren’t working. She soon went into a coma, then organ failure and subsequently died.
An Eli Lilly spokesperson told the BBC that patient safety is its top priority. “We are committed to continually monitoring, evaluating and reporting safety information for all Lilly medicines,” they said.
“Mounjaro was approved based on extensive assessment of the benefits and risks of the medicine, and we provide information about the benefits and risks of all our medicines to regulators around the world to ensure the latest information is available for prescribers,” they added…
READ FULL ARTICLE HERE… (childrenshealthdefense.org)
Home | Caravan to Midnight (zutalk.com)
